In order to determine if combined p110 isoform inhibition could achieve similar anti-tumor associated effects to single p110 isoform inhibition at significantly lower doses of the inhibitors, combination of the two most effective inhibitors, BYL-719 (p110α) and CAL-101 (p110δ) were compared to AZD-8835, a selective bi-specific inhibitor of p110 isoforms α and δ, which is currently in phase I trials. This evidence concerns the gene PIK3CD and neoplasm.